MELBOURNE, Australia - After four years of planning and construction, CSL’s new Global Headquarters and Center for R&D has opened its doors to welcome the first of 850+ employees who will work in the 18-story building. A full opening is expected in July after completion of the building’s labs.
CSL is a global biotech company with business units that include CSL Behring, which makes medicines for rare and serious diseases; CSL Seqirus, which develops and manufactures vaccines; and CSL Vifor, newly acquired in 2022 and specialising in iron deficiency and nephrology (kidney care.)
The new location enables CSL to collaborate with external partners, access the best resources to improve R&D and optimise technological advances for the good of patients and public health, CSL CEO Paul McKenzie said.
“Not only do we position ourselves strongly in the heart of Melbourne, but we bring together many elements of our expansive Melbourne teams under the one roof, enhancing our Values, including collaboration and innovation, within our internal teams, and truly enabling us to embrace ‘Working Better Together’,” he said.